Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof
US-2024390298-A1 · Nov 28, 2024 · US
Composition of 5-nitrobenzoate derivatives as anti-metastatic agent that inhibits tumor cell-induced platelet aggregation
US9604910B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9604910-B2 |
| Application number | US-201414287735-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 27, 2014 |
| Priority date | Jul 9, 2012 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.
First claim
Opening claim text (preview).
What is claimed is: 1. A 5-nitrobenzoate derivative represented by formula I, wherein R is one selected from a group consisting of an unsubstituted benzoyl moiety a mono-substituted benzoyl moiety a di-substituted benzoyl moiety and a tri-substituted benzoyl moiety each of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is one selected from a group consisting of a fluoride, a chloride, a bromide, an iodide and a methyl group. 2. The 5-nitrobenzoate derivative according to claim 1 being prepared as a pharmaceutical composition. 3. The 5-nitrobenzoate derivative according to claim 1 being prepared as a pharmacologically acceptable salt. 4. The 5-nitrobenzoate derivative according to claim 1 , wherein R is the unsubstituted benzoyl moiety
Assignees
Inventors
Classifications
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title
having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals · CPC title
- A61K31/166Primary
having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9604910B2 cover?
- Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platel…
- Who is the assignee on this patent?
- Univ Chang Gung
- What technology area does this patent fall under?
- Primary CPC classification A61K31/166. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).